Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
|Slideshows|April 17, 2018
April Research Update: Major Depressive Disorder
Author(s)Mark L. Fuerst
Relapse in MDD is associated with morphologic brain changes; stopping exercise may increase depressive symptoms; and inflammatory biomarkers may predict which treatment-resistant MDD patients benefit from ECT.
Advertisement
Advertisement
Related to this article
GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
2
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Updates on CTx-1301, NDA Resubmission After FDA Complete Response Letter
5